Lyell Immunopharma Presents IMPT-314 Data at Major Conference
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a pioneering clinical-stage company, is set to showcase pivotal data from its Phase 1-2 clinical trial of IMPT-314, a promising new therapy for large B-cell lymphoma. This presentation, led by Dr. Sarah M. Larson from UCLA, is slated for the upcoming American Society of Hematology (ASH) Annual Meeting, marking a significant step forward in advancing CAR T-cell therapies.
Overview of IMPT-314 and Its Significance
IMPT-314 stands out as a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate. It aims to provide a new avenue of hope for patients battling aggressive B-cell non-Hodgkin’s lymphoma, a type of cancer that can prove particularly challenging to treat. The therapy has received Fast Track Designation from the U.S. Food and Drug Administration, highlighting its potential in transforming the treatment landscape for relapsed or refractory aggressive B-cell lymphoma.
Details of the Presentation
The presentation will include first results from the trial, detailing the efficacy and safety of IMPT-314 in patients. The specifics are as follows:
- Session Name: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III
- Publication Number: 4824
- Presentation Date & Time: December 9, 2024, from 6:00 PM to 8:00 PM
- Location: San Diego Convention Center, Halls G-H
The Mission and Vision of Lyell Immunopharma
Headquartered in South San Francisco, Lyell is dedicated to developing next-generation CAR T-cell therapies. The company focuses on providing solutions for patients suffering from both solid tumors and hematologic malignancies. The innovative product candidates developed by Lyell are designed to generate T cells capable of resisting exhaustion, which can enhance the durability of the treatments they provide. This unique approach aims to drive long-lasting clinical responses and improve patient outcomes.
Lyell's Innovative Approach to Cancer Therapy
With a robust pipeline backed by cutting-edge technology, Lyell is striving to revolutionize cancer treatment. Their proprietary methods are geared towards creating a new class of T cells that not only combat cancer effectively but also maintain a level of 'stemness,' allowing them to persist and act over time. This could potentially lead to more consistent and resilient responses compared to current therapies.
The Future of CAR T-cell Therapies
As researchers gather in San Diego for the ASH Annual Meeting, Lyell’s commitment to innovation in CAR T-cell therapy comes at a critical time. The advancements made through trials such as that of IMPT-314 could set new benchmarks in cancer care, providing desperate patients with options that transform their treatment journey. The clinical data presented will be scrutinized worldwide, with many hoping for positive outcomes that translate into broader treatment options.
Contact Information for Lyell Immunopharma
For more details about Lyell and its commitment to advancing cancer therapies, interested parties can reach out to Ellen Rose, Senior Vice President of Communications and Investor Relations at erose@lyell.com.
Frequently Asked Questions
What is IMPT-314?
IMPT-314 is a dual-targeting CAR T-cell therapy aimed at treating aggressive B-cell lymphoma.
Who presented the data for IMPT-314?
The clinical data will be presented by Dr. Sarah M. Larson from UCLA.
Where is the ASH Annual Meeting taking place?
The ASH Annual Meeting will occur at the San Diego Convention Center.
What designation has IMPT-314 received from the FDA?
IMPT-314 has received Fast Track Designation from the U.S. FDA for its potential benefits in treating relapsed/refractory aggressive B-cell lymphoma.
How does Lyell aim to improve cancer therapy?
Lyell's innovative approach involves developing T cells that resist exhaustion and maintain behavioral qualities akin to stem cells, improving therapeutic durability.
